Self-sampling for cervical cancer screening – what is it and what does evidence from Europe tell us about whether it provides any benefits compared to traditional ways of screening?
Regular screening is crucial for preventing cervical cancer or identifying cancer at an early stage, when treatment is most likely to be successful. Screening is particularly important for women who did not receive the HPV vaccine; in the UK, that means most women over the age of 30. Many European countries, including the UK, have Read More >
Publication of our economic evaluation comparing two cervical screening strategies in Belgium: HPV primary versus co-testing
Health economic evaluation of an mRNA HR-HPV assay versus a DNA HR-HPV assay for the proposed French cervical screening programme
Further evidence that rapid near-patient testing for chlamydia and gonorrhoea in sexual health clinics benefits patient care
A health economic model to estimate the costs and benefits of an mRNA vs DNA high-risk HPV assay in a hypothetical HPV primary screening algorithm in Ontario, Canada
Evaluating the benefits and costs of using an mRNA versus DNA HR-HPV assay in the National Cervical Screening Programme in the Netherlands
Modelling the impact of using a DNA compared to mRNA HPV assay as part of the cervical screening programmes in Sweden and Denmark
Estimating the costs and benefits of HR-HPV assay choice in a theoretical HPV primary cervical screening algorithm in Ontario, Canada
Evaluating the choice of HPV assay in the French cervical screening programme with a decision tree model
A cost effectiveness analysis of repeat screening for syphilis in pregnancy as an alternative screening strategy in the UK
